{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Poorly+Differentiated+Carcinoma&page=2", "query": { "condition": "Poorly Differentiated Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Poorly+Differentiated+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T03:07:43.952Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00237627", "title": "Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Ovarian Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "PS-341", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Velcade", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2001-05", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-05-18", "last_synced_at": "2026-07-23T03:07:43.952Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00237627" }, { "nct_id": "NCT02973997", "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Columnar Cell Variant Thyroid Gland Papillary Carcinoma", "Follicular Variant Thyroid Gland Papillary Carcinoma", "Metastatic Thyroid Gland Follicular Carcinoma", "Metastatic Thyroid Gland Papillary Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Follicular Carcinoma", "Recurrent Thyroid Gland Papillary Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage III Thyroid Gland Follicular Carcinoma AJCC v7", "Stage III Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7", "Tall Cell Variant Thyroid Gland Papillary Carcinoma", "Thyroid Gland Hurthle Cell Carcinoma", "Unresectable Differentiated Thyroid Gland Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Lenvatinib Mesylate", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2018-02-07", "completion_date": "2023-10-08", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-07-23T03:07:43.952Z", "location_count": 7, "location_summary": "Torrance, California • Aurora, Colorado • Boston, Massachusetts + 4 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02973997" }, { "nct_id": "NCT01811212", "title": "Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Stage I Thyroid Gland Follicular Carcinoma", "Stage I Thyroid Gland Papillary Carcinoma", "Stage II Thyroid Gland Follicular Carcinoma", "Stage II Thyroid Gland Papillary Carcinoma", "Stage III Thyroid Gland Follicular Carcinoma", "Stage III Thyroid Gland Papillary Carcinoma", "Stage IVA Thyroid Gland Follicular Carcinoma", "Stage IVA Thyroid Gland Papillary Carcinoma", "Stage IVB Thyroid Gland Follicular Carcinoma", "Stage IVB Thyroid Gland Papillary Carcinoma", "Stage IVC Thyroid Gland Follicular Carcinoma", "Stage IVC Thyroid Gland Papillary Carcinoma", "Tall Cell Variant Thyroid Gland Papillary Carcinoma", "Thyroid Gland Oncocytic Follicular Carcinoma" ], "interventions": [ { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2013-05-08", "completion_date": "2017-10-09", "has_results": true, "last_update_posted_date": "2018-04-03", "last_synced_at": "2026-07-23T03:07:43.952Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Jacksonville, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01811212" }, { "nct_id": "NCT07707895", "title": "A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Large Cell Neuroendocrine Lung Carcinoma", "Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology", "Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology" ], "interventions": [ { "name": "Obrixtamig", "type": "DRUG" }, { "name": "ZL-1310", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-08-26", "completion_date": "2030-04-26", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-07-23T03:07:43.952Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Lexington, Kentucky", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07707895" }, { "nct_id": "NCT07460765", "title": "Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hnscc", "Head and Neck", "Squamous Cell Cancer", "Squamous Carcinoma", "Squamous Cell Cancer of Head and Neck (SCCHN)", "Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)", "Squamous Cell Carcinoma Mouth", "Squamous Carcinoma Poorly Differentiated", "Squamous Cell Cancer of the Head and Neck", "Squamous Cell Carcinoma (SCC) of the Oral Cavity", "Squamous Cell Carcinoma (SCC)" ], "interventions": [ { "name": "Nivo800", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-07", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-23T03:07:43.952Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07460765" }, { "nct_id": "NCT03896958", "title": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer, All Types", "Cancer of Liver", "Cancer of Stomach", "Cancer of Head and Neck", "Cancer of Rectum", "Cancer of Kidney", "Cancer of Esophagus", "Cancer of Colon", "Cancer Skin", "Cancer of Cervix", "Cancer, Metastatic", "Cancer of Larynx", "Cancer of Neck", "Cancer of Lung", "Cancer of Brain and Nervous System", "Cancer of Vulva, Disseminated", "Cancer of Pancreas", "Sarcoma", "GIST", "Small-cell Lung Cancer", "Adenocarcinoma Lung", "Cancer of Prostate", "Cancer, Advanced", "Adrenal Cancer", "Testicular Cancer", "Uterine Cancer", "Bronchoalveolar Cell Lung Cancer", "Cancer Unknown Primary", "Glioblastoma Multiforme", "Oligodendroglioma", "Breast Cancer", "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Cholangiocarcinoma", "Squamous Cell Carcinoma", "Transitional Cell Carcinoma", "Cancer, Other", "Cancer, Anal", "Melanoma", "Cancer, Bile Duct", "Cancer, Bladder", "Cancer Cords Vocal", "Cancers Cell Neuroendocrine", "Cancer Differentiated Poorly", "Cancer, Anaplastic Thyroid" ], "interventions": [], "intervention_types": [], "sponsor": "SpeciCare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Month to 99 Years" }, "enrollment_count": 1000, "start_date": "2019-03-21", "completion_date": "2024-03-12", "has_results": false, "last_update_posted_date": "2020-12-04", "last_synced_at": "2026-07-23T03:07:43.952Z", "location_count": 1, "location_summary": "Gainesville, Georgia", "locations": [ { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896958" }, { "nct_id": "NCT01156142", "title": "Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer", "Mucositis", "Oral Complications of Radiation Therapy", "Pain" ], "interventions": [ { "name": "doxepin hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2010-12", "completion_date": "2015-03-02", "has_results": true, "last_update_posted_date": "2017-08-09", "last_synced_at": "2026-07-23T03:07:43.952Z", "location_count": 120, "location_summary": "Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT01156142" }, { "nct_id": "NCT00499733", "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cryoablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2013-01-09", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-07-23T03:07:43.952Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499733" }, { "nct_id": "NCT02628379", "title": "Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neoplasms, Unknown Primary", "CUP", "Metastatic Disease", "Poorly Differentiated Adenocarcinoma", "Poorly Differentiated Carcinoma", "Squamous Carcinoma Poorly Differentiated" ], "interventions": [], "intervention_types": [], "sponsor": "Foundation Medicine", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2015-05", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2018-07-10", "last_synced_at": "2026-07-23T03:07:43.952Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02628379" }, { "nct_id": "NCT04544111", "title": "PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer", "Thyroid Cancer, Follicular", "Papillary Thyroid Cancer", "Follicular Thyroid Cancer", "Hurthle Cell Tumor", "Poorly Differentiated Thyroid Gland Carcinoma", "Hurthle Cell Thyroid Neoplasia" ], "interventions": [ { "name": "Trametinib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "PDR001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2020-09-02", "completion_date": "2026-09-02", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-07-23T03:07:43.952Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04544111" } ] }